NOT FOR DISTRIBUTION TO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESVancouver, British Columbia, May 29, 2025 (GLOBE NEWSWIRE) -- NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that it has closed its previously-announced brokered private placement financing and concurrent non-brokered financing of units (the “Units”) for gross proceeds of $6,000,000 (the “Offering”). Each Unit, priced at $0.30 per Unit (the “Issue Price”), consists of one c ...

文章核心观点 ORIC Pharmaceuticals宣布通过私募配售向机构和专业医疗投资者出售约1920万股普通股或预融资认股权证，预计融资约1.25亿美元，资金将用于研发和运营，预计可支撑到2027年下半年及首个ORIC - 944前列腺癌3期试验主要终点结果公布 [1][3] 融资情况 - 公司将以每股6.50美元（或每份预融资认股权证6.4999美元）价格，向特定机构和专业医疗投资者私募配售约1920万股普通股或预融资认股权证，较2025年5月23日10日成交量加权平均价溢价约18% [1] - 预融资认股权证行使价为每股0.0001美元，可立即行使，直至全部行使完毕 [1] - 融资预计2025年5月29日完成，需满足惯常成交条件 [1] - 融资由SR One牵头，新老机构投资者参与，包括Point72、Viking Global Investors等 [1][2] - 私募配售预计毛收入约1.25亿美元，未扣除发行相关费用 [1] 资金用途 - 公司拟用融资净收入资助临床阶段候选产品和研究项目研发，以及用作营运资金和一般公司用途 [3] - 融资所得与现有现金、现金等价物和有价证券结合，预计可支撑当前运营计划到2027年下半年，并覆盖首个ORIC - 944前列腺癌3期试验主要终点结果公布 [3] 公司概况 - ORIC Pharmaceuticals是临床阶段生物制药公司，致力于克服癌症耐药性，改善患者生活 [6] - 临床阶段候选产品包括用于前列腺癌的ORIC - 944和用于多种基因定义癌症的ORIC - 114，还在开发针对其他癌症耐药机制的精准药物 [6] - 公司在加州南旧金山和圣地亚哥设有办公室，更多信息可访问官网或关注社交平台 [6] 证券登记 - 上述证券未根据1933年《证券法》注册，除有效注册声明或适用豁免外，不得在美国发售或出售 [4] - 公司同意向美国证券交易委员会提交注册声明，登记普通股和预融资认股权证行使时发行普通股的转售，转售注册声明下证券发售将通过招股说明书进行 [4]

“NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.” VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that, due to strong investor demand, it has agreed with Clarus Securities Inc. (the “Lead Agent”), as Lead Agent and sole bookrunner, on behalf of a syndicate of agents (the “Agents”), to increase the size of its previously announced $5,500 ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Private Placement”) of 4,000,000 common shares in the capital of the Company (the “Common Shares”) at an issue price of C$0.25 per Common Share for aggregate gross pr ...

“NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.” VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that, due to strong investor demand, it has agreed with Clarus Securities Inc. (the “Lead Agent”), as Lead Agent and sole bookrunner, on behalf of a syndicate of agents (the “Agents”), to increase the size of its previously announced $5,000 ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, BC, May 16, 2025 (GLOBE NEWSWIRE) -- Bessor Minerals Inc. (TSXV:BST) ("Bessor" or the “Corporation”) is pleased to announce that it intends to complete a non-brokered private placement offering of up to 6,250,000 common shares in the capital of Bessor (the “Offered Shares”) at a price of $0.02 per Offered Share, for gross proceeds of up to $125,000 (the “Private ‎Placement”). ‎ Bessor intends to com ...